NeutroSpec Promos Tout Broad, Unsupported Indications, FDA Chides
This article was originally published in The Pink Sheet Daily
Executive Summary
The withdrawn imaging agent is cited for violations made during the 2005 American Pharmaceutical Association annual meeting.
You may also be interested in...
NeutroSpec Pulled From The Market
FDA "reconsidered" the risk/benefit balance for Mallinckrodt/Palatin Technologies' appendicitis imaging agent, which has been associated with cardiopulmonary events.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.